Trial
NCT02213744
MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Merrimack Pharmaceuticals
Collaborators
—
Condition
Breast Cancer
Intervention
MM-302
Why stopped
Felt not to show benefit over control per DMC and confirmed via futility analysis
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-01-06